Contact
Please use this form to send email to PR contact of this press release:
Referral: Janus kinase inhibitors (JAKi), tofacitinib, abrocitinib, baricitinib, upadacitinib, filgotinib, Article 20 procedures, European Commission final decision, 23/01/2023, 10/03/2023, 22/05/2023
TO: